Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:
“LET’S PLAY DEVIL’S ADVOCATE:
Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –
Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.
I broke it down—with counterarguments .
Do Check this out.”
Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32